![]() |
|
|
|
You are here: Skin Care Research >
Author: Dreno B, Katsambas A, Pelfini C, Plantier D, Jancovici E, Ribet V, Nocera T, Morinet P, Khammari A
Author affiliation: A. Sygros Hospital, University of Athens, Athens, Greece. brigitte.dreno@wanadoo.fr
Publication date & source: 2007, Dermatology., 214(3):260-7.
Publication type: Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
BACKGROUND: Acne often results in permanent, badly tolerated, difficult to treat scars. OBJECTIVE: To evaluate the efficacy and safety of a 0.1% retinaldehyde/6% glycolic acid (RALGA) cream at preventing and treating acne scarring in patients previously treated for moderate acne. METHODS: A double-blind vehicle-controlled study was conducted in 145 patients randomized to apply RALGAor vehicle cream every evening for 3 months. Global scarring score and patient's assessment of global efficacy, then residual acne lesions, quality of life and tolerance were evaluated at inclusion and each month until study completion. RESULTS: Global scarring score, number of inflammatory lesions and comedones significantly improved in each group from day 28 (p<0.0001). Number of inflammatory lesions were significantly decreased only in the RALGA group. RALGA cream was more efficient than vehicle on scarring after 3 months in compliant patients (p=0.007) due to erythema and hyperpigmentation improvement. CONCLUSION: RALGA cream is efficient at preventing and treating acne scarring in patients with moderate acne. Copyright (c) 2007 S. Karger AG, Basel.
Home | About Us | Contact Us | Ask a Question | Resources Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com Site Disclaimer | Copyright Certification
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||